Big Pharma Split Corp.
Big Pharma Split Corp. (PRM.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
prm.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Big Pharma Split Corp. (PRM.TO) measures how much investors pay for each dollar of the company's trailing earnings. PRM.TO's current PE ratio of 3.81x is calculated by dividing its stock price of $13.75 by its TTM earnings per share of $3.61. −73.4% discount vs 5Y avg 14.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%6.5x
MedianQ3 · 75%59.5x
Max
At 3.81x, PRM.TO's current P/E is lower than in 0% of its annual fiscal year readings over the past 7 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Asset Management · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Big Pharma Split Corp.You PRM.TO | $18M | 3.81x | +167.8% | $3.61 |
 Big Banc Split Corp. BNK.TO | $23M | N/A | — | $0.00 |
 Elysee Development Corp. ELC.V | $18M | 1.48x | +4.0% | $0.34 |
 Faircourt Gold Income Corp. FGX.NE | $17M | 1.59x | +12.0% | $4.24 |
 GOAT Industries Ltd. GOAT.CN | $2M | N/A | — | -$0.18 |
 Nations Royalty Corp. NRC.V | $11M | N/A | — | -$0.20 |
 Planet Ventures Inc. PXI.CN | $32M | 1.20x | -16.0% | $0.05 |
Industry Average 3 peers with valid PE | — | 1.42x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 3.87x | $3.59 | — | |
2024-12-31 FY2024 | — | $-0.47 | — | |
2023-12-31 FY2023 | — | $-0.11 | — | |
2022-12-31 FY2022 | 7.00x | $2.08 | +79.5% | |
2021-12-31 FY2021 | 3.90x | $3.76 | -92.2% | |
2020-12-31 FY2020 | 50.27x | $0.27 | +671.8% | |
2019-12-31 FY2019 | 6.51x | $2.16 | +8.1% | |
2018-12-31 FY2018 | 6.02x | $2.06 | -89.9% | |
2017-12-31 FY2017 | 59.54x | $0.24 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Big Pharma Split Corp. (PRM.TO) measures how much investors pay for each dollar of the company's trailing earnings. PRM.TO's current PE ratio of 3.81x is calculated by dividing its stock price of $13.75 by its TTM earnings per share of $3.61.
Frequently asked questions
PRM.TO pe ratio · 6 questionsPRM.TO's current PE ratio is 3.81x as of 2026-06-08, based on a stock price of $13.75 and TTM EPS of $3.61. Data sourced from Financial Modeling Prep via PRM.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Big Pharma Split Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08